Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 70 years of age or older~* Gastric cancer, locally advanced or metastatic~* No previous adjuvant treatment (surgery, radiotherapy, chemotherapy) in the last 6 months~* One measurable lesion~* ECOG \< 3~* Biology and biochemistry within normal limits~* Life expectancy \> 12 weeks~Exclusion Criteria:~* Other palliative chemotherapy for this cancer~* Other cancer in the last 5 years~* Previous treatment with irinotecan~* Atropine treatment not possible~* Concomitant cancer therapy except bone radiotherapy~* Metastases to brain or meninges with symptoms~* Other severe pathology uncontrolled~* Problem of compliance

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Irinotecan associated to fluorouracil and leucovorin (Type: EXPERIMENTAL): On D1, as a single 90-minute intravenous infusion diluted in 250 ml of saline (sodium chloride a 9 ‰), or isotonic glucose, at a dose of 180 mg/m2. Dosage adjustments are provided in case of severe toxicity.~Then 5FU/ folinic acid: 400 mg/m2 of 5-FU as an IV bolus followed by a continuous 2400 mg/m2 infusion over 46 hours with 400 mg/m2 of folinic acid or 200 mg/m2 of l-folinic acid as a 2-hour infusion before 5-FU administration.~Doses of 5-FU are adjusted according to clinical tolerance. Resume on D15 for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).